DARE - Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
- Women health firm Daré Bioscience ( NASDAQ: DARE ) announced an exclusive license agreement with clinical-stage biopharma firm Organon ( NYSE: OGN ) to commercialize Xaciato, DARE's treatment of bacterial vaginosis in patients 12 years of age and older.
- Under the agreement, Daré will receive a $10M upfront payment from Organon and is eligible to receive potential milestone payments of up to $182.5M and tiered double-digit royalties based on net sales.
- Xaciato will be commercially available in the U.S. in Q4, DARE said.
- The companies entered into the agreement on March 31.
For further details see:
Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy